FDA Approves Biosimilar That Can Treat Crohn's Disease, Psoriasis
The FDA has approved Wezlana, a biosimilar of Stelara, to treat a variety of rheumatic conditions, including psoriatic arthritis, Crohn's disease, and plaque psoriasis.
The FDA has approved Wezlana, a biosimilar of Stelara, to treat a variety of rheumatic conditions, including psoriatic arthritis, Crohn's disease, and plaque psoriasis.
Our website services, content, and products are for informational purposes only. Healthline does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Healthline encourages you to make any treatment decisions with your healthcare professional. Healthline is owned by RVO Health.
No comments:
Post a Comment
Keep a civil tongue.